Abbott Laboratories (DE:ABL)
NYSE:ABL
ABL Stock Chart & Stats
€81.88
-€0.02(-0.02%)
At close: 4:00 PM EST
€81.88
-€0.02(-0.02%)
Day’s Range― - ―
52-Week Range€70.10 - €119.50
Previous CloseN/A
Volume11.00
Average Volume (3M)1.72K
Market Cap
€136.60B
Enterprise Value€176.31B
Total Cash (Recent Filing)€7.29B
Total Debt (Recent Filing)€34.05B
Price to Earnings (P/E)25.2
Beta0.30
Next Earnings
Jul 16, 2026EPS Estimate
1.11Next Dividend Ex-DateN/A
Dividend Yield1.89%
Share Statistics
EPS (TTM)3.60
Shares Outstanding1,741,812,400
10 Day Avg. Volume1,959
30 Day Avg. Volume1,715
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)4.20
Price to Sales (P/S)4.94
P/FCF Ratio29.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€103.90Price Target Upside26.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)4.71
Revenue Forecast (FY)€43.39B
Bulls Say, Bears Say
Bulls Say
Diversified Healthcare PortfolioAbbott’s multi‑segment model (Devices, Diagnostics, Nutrition, Established Pharmaceuticals) spreads revenue across procedure‑driven, recurring consumables, consumer retail and international generics. This diversification lowers single‑market cyclicality, supports steadier revenue and cross‑sell over multi‑year horizons.
Conservative Leverage And Balance‑sheet StrengthA low debt‑to‑equity ratio provides capacity to absorb strategic acquisitions, fund R&D and maintain dividends without immediate refinancing pressure. This balance‑sheet flexibility supports long‑term investment in pipeline and commercialization while limiting liquidity stress through economic cycles.
Strategic Exact Sciences Acquisition Expands DiagnosticsAdding Exact Sciences meaningfully scales Abbott’s cancer screening and precision oncology capabilities, creating a structural growth vertical. The bolt‑on expands recurring screening revenue, enhances cross‑sell into labs and provider networks, and positions Abbott in a large, growing ($~60B) diagnostics market over several years.
Bears Say
Large Debt Issuance Raises Financing BurdenA $20B senior‑notes financing materially increases contractual interest and principal obligations and reduces near‑term financial flexibility. Even with long maturities, higher fixed and floating interest exposure raises refinancing and rating risks and constrains capital allocation until leverage normalizes post‑integration.
Weakening Free Cash Flow MomentumDeclining FCF growth and sub‑par cash conversion signal weaker earnings quality and less internal funding for capex, R&D, or debt paydown. Persistent cash‑flow softness would limit Abbott’s ability to deleverage after the Exact Sciences deal and reduce strategic optionality for buybacks or opportunistic M&A.
Structural China VBP And Nutrition Volume PressureChina volume‑based procurement and ongoing nutrition volume weakness are structural headwinds that compress pricing and volumes in important markets. These trends can depress segment growth and margins over multiple quarters, requiring repricing, cost action or portfolio adjustments to restore durable revenue trajectories.
Abbott Laboratories News
ABL FAQ
What was Abbott Laboratories’s price range in the past 12 months?
Abbott Laboratories lowest stock price was €70.10 and its highest was €119.50 in the past 12 months.
What is Abbott Laboratories’s market cap?
Abbott Laboratories’s market cap is €136.60B.
When is Abbott Laboratories’s upcoming earnings report date?
Abbott Laboratories’s upcoming earnings report date is Jul 16, 2026 which is in 37 days.
How were Abbott Laboratories’s earnings last quarter?
Abbott Laboratories released its earnings results on Apr 16, 2026. The company reported €0.998 earnings per share for the quarter, beating the consensus estimate of €0.993 by €0.004.
Is Abbott Laboratories overvalued?
According to Wall Street analysts Abbott Laboratories’s price is currently Undervalued.
Does Abbott Laboratories pay dividends?
Abbott Laboratories pays a Quarterly dividend of €0.534 which represents an annual dividend yield of 1.89%. See more information on Abbott Laboratories dividends here
What is Abbott Laboratories’s EPS estimate?
Abbott Laboratories’s EPS estimate is 1.11.
How many shares outstanding does Abbott Laboratories have?
Abbott Laboratories has 1,741,812,400 shares outstanding.
What happened to Abbott Laboratories’s price movement after its last earnings report?
Abbott Laboratories reported an EPS of €0.998 in its last earnings report, beating expectations of €0.993. Following the earnings report the stock price went down -3.728%.
Which hedge fund is a major shareholder of Abbott Laboratories?
Currently, no hedge funds are holding shares in DE:ABL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abbott Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€103.90 (26.90% Upside)
€103.90 (26.90% Upside)
Blogger Sentiment
Bullish
DE:ABL Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €978.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.61%
12-Months-Change
Fundamentals
Return on Equity
12.20%
Trailing 12-Months
Asset Growth
35.58%
Trailing 12-Months
Company Description
Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
ABL Company Deck
ABL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive outlook driven by solid device performance, completion and strategic value of the Exact Sciences acquisition (adding ~$3 billion of sales), strong pipeline progress, and underlying comparable sales and EPS growth. However, near-term headwinds remain: a notably weak respiratory season that hit molecular testing, ongoing Nutrition volume recovery, China VBP lingering effects, and modest EPS dilution from the acquisition. Management emphasized confidence in execution and an expectation of growth acceleration in the second half of the year, balancing near-term caution with medium- to long-term upside.View all DE:ABL earnings summariesABL Net sales Breakdown
12.49% Established Pharmaceutical Products
19.06% Nutritional Products
20.16% Diagnostic Products
48.25% Medical Devices
0.04% Other
ABL Stock 12 Month Forecast
Average Price Target
€103.90
▲(26.90% Upside)
Technical Analysis
Options Prices
Currently, No data available
---